CAS 565451-13-0
:Raxibacumab
Description:
Raxibacumab is a monoclonal antibody that is primarily used as a therapeutic agent against inhalational anthrax, caused by the bacterium Bacillus anthracis. It is designed to bind to protective antigen component of the anthrax toxin, thereby preventing the toxin from entering and affecting host cells. Raxibacumab is produced using recombinant DNA technology and is classified as a human IgG1 antibody. Its mechanism of action involves neutralizing the effects of anthrax toxins, which can lead to severe illness or death if left untreated. The drug is administered via intravenous infusion and is typically used in conjunction with appropriate antibacterial therapy. Raxibacumab has been granted FDA approval for use in specific emergency situations, particularly for individuals who have been exposed to anthrax spores. Its safety profile includes potential side effects such as infusion-related reactions, but it is generally well-tolerated. Overall, Raxibacumab represents a critical tool in biodefense and public health for managing anthrax exposure.
Formula:Unspecified
Synonyms:- Immunoglobulin G1, anti-(anthrax protective antigen) (human monoclonal PA heavy chain), disulfide with human monoclonal PA λ-chain, dimer
- ABthrax
- Raxibacumab
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 3 products.
Raxibacumab
CAS:Raxibacumab (ABthrax) is a humanized antibody targeting the protective antigen of Bacillus anthracis, with anti-infection activity.Purity:95%Color and Shape:LiquidMolecular weight:142.96 kDaRaxibacumab
CAS:Human monoclonal antibody against the protective antigen of anthrax toxin; prophylaxis and treatment of inhaled anthrax
